Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.76 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | STS | P08842 | 8/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.74 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA6 | P23280 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Acetate SCHEMBL6241050 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| Estrone Acetate SCHEMBL603954 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL1977541 | 0.94 | CYP3A4 (0.80) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL12216745 | 0.90 | CYP3A4 (0.75) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL9790047 | 0.89 | CYP3A4 (0.74) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL7989780 | 0.89 | CYP3A4 (0.74) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL6899365 | 0.89 | ESR1 (0.69) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL6899367 | 0.89 | ESR1 (0.69) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL7992527 | 0.89 | CYP3A4 (0.72) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 | |
| SCHEMBL27592877 | 0.89 | CYP3A4 (0.72) | CYP3A4LMNAMAPTSMN1; SMN2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023250513-A1 | 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115813902-A | Use of substituted hexitols for the treatment of malignant tumors | 德玛公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115778934-A | Use of substituted hexitols for the treatment of malignant tumors | 德玛公司 | 2023-03-14 | — | — | CN | disclosed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| US-20220193024-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-06-23 | — | — | US | disclosed |
| CN-114599368-A | Tetracyclic compounds and salts, compositions, and methods of use thereof | 生华生物科技股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220142966-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-05-12 | — | — | US | disclosed |
| US-11234955-B2 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-02-01 | — | — | US | disclosed |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| EP-2958928-B1 | ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3) | Bayer Pharma AG (DE) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142966-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | MGMT, MPG, HDAC7 | CYP3A4 3705/4885LMNA 3848/4885MAPT 4150/4885 |
| US-20220193024-A1 | USE OF SUBSTITUTED HEXITOLS INCLUDING DIANHYDROGALACTITOL AND ANALOGS TO TREAT NEOPLASTIC DISEASE AND CANCER STEM CELLS INCLUDING GLIOBLASTOMA MULTIFORME AND MEDULLOBLASTOMA | MGMT, MPG, HDAC7 | CYP3A4 3705/4885LMNA 3848/4885MAPT 4150/4885 |
| US-11234955-B2 | Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma | MGMT, MPG, HDAC7 | CYP3A4 3705/4885LMNA 3848/4885MAPT 4150/4885 |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | HLCS, NCL, NUDC | CYP3A4 1126/4885LMNA 19/4885MAPT 3914/4885 |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | CYP3A4 1198/4885LMNA 1760/4885MAPT 602/4885 |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | HLCS, NCL, NUDC | CYP3A4 1368/4885LMNA 30/4885MAPT 3995/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | CYP3A4 2649/4885LMNA 4788/4885MAPT 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.